Jazz Pharmaceuticals plc
Waterloo Exchange
Fifth Floor Waterloo Road
Dublin D04 E5W7
Ireland
353 1 634 7800
https://www.jazzpharma.com
版塊: Healthcare
行業: Biotechnology
全職員工: 2,800
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Bruce C. Cozadd | Co-Founder, Chairman & CEO | 2.44M | 無 | 1964 |
| Ms. Renee D. Gala | President & COO | 1.36M | 無 | 1972 |
| Ms. Patricia Carr | Senior VP & Chief Accounting Officer | 633.4k | 無 | 1971 |
| Ms. Neena M. Patil J.D. | Executive VP & Chief Legal Officer | 1.01M | 無 | 1975 |
| Dr. Robert Iannone M.D. | Executive VP and Global Head of Research & Development | 1.19M | 無 | 1967 |
| Mr. Philip L. Johnson | Executive VP & CFO | 無 | 無 | 1964 |
| Ms. Andrea N. Flynn Ph.D. | VP & Head of Investor Relations | 無 | 無 | 無 |
| Ms. Heidi Manna | Executive VP & Chief People Officer | 無 | 無 | 1972 |
| Dr. Jed Black M.D. | Senior Vice President of Sleep & CNS Medicine | 無 | 無 | 無 |
| Ms. Samantha Pearce | Senior Vice President of Europe & International | 無 | 無 | 1966 |
描述
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
公司管治
截至 2024年5月1日 止，Jazz Pharmaceuticals plc 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：7；董事會：3；股東權利：3；現金賠償：4。
